2015-05-22 |
2015-05-22 |
PS
Planned sale
|
Schwartz Steven Daniel
Non-Executive Director
|
5,196
-1.3%
38.88
202,043
USD
|
5,196
-1.3%
|
38.88
|
202,043
USD
|
|
2015-05-22 |
2015-05-21 |
PS
Planned sale
|
Gasmi Mehdi
VP, Pharmaceutical Development
Officer
|
500
-6.7%
38.87
19,435
USD
|
500
-6.7%
|
38.87
|
19,435
USD
|
|
2015-05-21 |
2015-05-19 |
PS
Planned sale
|
Blumenkranz Mark S.
Non-Executive Director
|
1,000
-8.7%
36.91
36,911
USD
|
1,000
-8.7%
|
36.91
|
36,911
USD
|
|
2015-05-21 |
2015-05-19 |
PS
Planned sale
|
Blumenkranz Mark S.
Non-Executive Director
|
1,000
-8.7%
36.91
36,911
USD
|
1,000
-8.7%
|
36.91
|
36,911
USD
|
|
2015-05-18 |
2015-05-15 |
PS
Planned sale
|
Blumenkranz Mark S.
Non-Executive Director
|
4,525
-0.8%
36.00
162,886
USD
|
4,525
-0.8%
|
36.00
|
162,886
USD
|
|
2015-05-15 |
2015-05-14 |
PS
Planned sale
|
Gasmi Mehdi
VP, Pharmaceutical Development
Officer
|
500
-6.7%
35.31
17,656
USD
|
500
-6.7%
|
35.31
|
17,656
USD
|
|
2015-05-13 |
2015-05-13 |
PS
Planned sale
|
Bain Linda
Chief Financial Officer
Officer
|
285
-3.1%
34.94
9,959
USD
|
285
-3.1%
|
34.94
|
9,959
USD
|
|
2015-05-12 |
2015-05-11 |
PS
Planned sale
|
Bain Linda
Chief Financial Officer
Officer
|
715
-7.4%
34.91
24,964
USD
|
715
-7.4%
|
34.91
|
24,964
USD
|
|
2015-05-12 |
2015-05-11 |
PS
Planned sale
|
Wachter Paul
Non-Executive Director
|
132
-0.3%
34.29
4,527
USD
|
132
-0.3%
|
34.29
|
4,527
USD
|
|
2015-05-12 |
2015-05-11 |
PS
Planned sale
|
Wachter Paul
Non-Executive Director
|
552
-1.3%
33.70
18,604
USD
|
552
-1.3%
|
33.70
|
18,604
USD
|
|
2015-05-08 |
2015-05-07 |
PS
Planned sale
|
Gasmi Mehdi
VP, Pharmaceutical Development
Officer
|
500
-6.7%
33.28
16,638
USD
|
500
-6.7%
|
33.28
|
16,638
USD
|
|
2015-05-06 |
2015-05-04 |
PS
Planned sale
|
Hull Hans
SVP, Business Operations
Officer
|
5,000
-30.6%
30.87
154,349
USD
|
5,000
-30.6%
|
30.87
|
154,349
USD
|
|
2015-05-06 |
2015-05-04 |
PS
Planned sale
|
Bain Linda
Chief Financial Officer
Officer
|
2,500
-21.7%
31.59
78,972
USD
|
2,500
-21.7%
|
31.59
|
78,972
USD
|
|
2015-04-30 |
2015-04-28 |
PS
Planned sale
|
Gasmi Mehdi
VP, Pharmaceutical Development
Officer
|
1,000
-12.5%
35.67
35,667
USD
|
1,000
-12.5%
|
35.67
|
35,667
USD
|
|
2015-04-23 |
2015-04-21 |
PS
Planned sale
|
Gasmi Mehdi
VP, Pharmaceutical Development
Officer
|
1,000
-100.0%
39.21
39,211
USD
|
1,000
-100.0%
|
39.21
|
39,211
USD
|
|
2015-04-20 |
2015-04-16 |
PS
Planned sale
|
Blumenkranz Mark S.
Non-Executive Director
|
200
-0.0%
42.04
8,408
USD
|
200
-0.0%
|
42.04
|
8,408
USD
|
|
2015-04-15 |
2015-04-14 |
PS
Planned sale
|
Gasmi Mehdi
VP, Pharmaceutical Development
Officer
|
1,000
-100.0%
39.45
39,448
USD
|
1,000
-100.0%
|
39.45
|
39,448
USD
|
|
2015-04-15 |
2015-04-14 |
PS
Planned sale
|
Zygtech, LLC
Major owner
|
4,600
-0.2%
39.93
183,663
USD
|
4,600
-0.2%
|
39.93
|
183,663
USD
|
|
2015-04-15 |
2015-04-13 |
PS
Planned sale
|
Wachter Paul
Non-Executive Director
|
24
-0.1%
40.74
978
USD
|
24
-0.1%
|
40.74
|
978
USD
|
|
2015-04-15 |
2015-04-13 |
PS
Planned sale
|
Wachter Paul
Non-Executive Director
|
338
-0.7%
39.85
13,468
USD
|
338
-0.7%
|
39.85
|
13,468
USD
|
|
2015-04-15 |
2015-04-13 |
PS
Planned sale
|
Zygtech, LLC
Major owner
|
776
-0.0%
40.69
31,579
USD
|
776
-0.0%
|
40.69
|
31,579
USD
|
|
2015-04-15 |
2015-04-13 |
PS
Planned sale
|
Zygtech, LLC
Major owner
|
7,350
-0.3%
39.94
293,587
USD
|
7,350
-0.3%
|
39.94
|
293,587
USD
|
|
2015-04-13 |
2015-04-09 |
PS
Planned sale
|
Schwartz Steven Daniel
Non-Executive Director
|
200
-0.0%
40.38
8,076
USD
|
200
-0.0%
|
40.38
|
8,076
USD
|
|
2015-04-08 |
2015-04-08 |
PS
Planned sale
|
Blumenkranz Mark S.
Non-Executive Director
|
2,500
-0.4%
39.94
99,841
USD
|
2,500
-0.4%
|
39.94
|
99,841
USD
|
|
2015-04-08 |
2015-04-07 |
PS
Planned sale
|
Blumenkranz Mark S.
Non-Executive Director
|
32
-0.3%
39.06
1,250
USD
|
32
-0.3%
|
39.06
|
1,250
USD
|
|
2015-04-08 |
2015-04-07 |
PS
Planned sale
|
Blumenkranz Mark S.
Non-Executive Director
|
968
-7.7%
38.59
37,353
USD
|
968
-7.7%
|
38.59
|
37,353
USD
|
|
2015-04-08 |
2015-04-07 |
PS
Planned sale
|
Blumenkranz Mark S.
Non-Executive Director
|
32
-0.3%
39.06
1,250
USD
|
32
-0.3%
|
39.06
|
1,250
USD
|
|
2015-04-08 |
2015-04-07 |
PS
Planned sale
|
Blumenkranz Mark S.
Non-Executive Director
|
968
-7.7%
38.59
37,353
USD
|
968
-7.7%
|
38.59
|
37,353
USD
|
|
2015-04-08 |
2015-04-07 |
PS
Planned sale
|
Blumenkranz Mark S.
Non-Executive Director
|
32
-0.3%
39.06
1,250
USD
|
32
-0.3%
|
39.06
|
1,250
USD
|
|
2015-04-08 |
2015-04-07 |
PS
Planned sale
|
Blumenkranz Mark S.
Non-Executive Director
|
968
-7.7%
38.59
37,353
USD
|
968
-7.7%
|
38.59
|
37,353
USD
|
|
2015-04-08 |
2015-04-07 |
PS
Planned sale
|
Blumenkranz Mark S.
Non-Executive Director
|
726
-0.1%
39.06
28,358
USD
|
726
-0.1%
|
39.06
|
28,358
USD
|
|
2015-04-08 |
2015-04-07 |
PS
Planned sale
|
Hull Hans
SVP, Business Operations
Officer
|
887
-21.1%
39.06
34,646
USD
|
887
-21.1%
|
39.06
|
34,646
USD
|
|
2015-04-08 |
2015-04-07 |
PS
Planned sale
|
Hull Hans
SVP, Business Operations
Officer
|
26,613
-86.3%
38.59
1,026,926
USD
|
26,613
-86.3%
|
38.59
|
1,026,926
USD
|
|
2015-04-08 |
2015-04-07 |
PS
Planned sale
|
Gasmi Mehdi
VP, Pharmaceutical Development
Officer
|
292
-100.0%
39.06
11,406
USD
|
292
-100.0%
|
39.06
|
11,406
USD
|
|
2015-04-08 |
2015-04-07 |
PS
Planned sale
|
Gasmi Mehdi
VP, Pharmaceutical Development
Officer
|
8,708
-96.8%
38.59
336,019
USD
|
8,708
-96.8%
|
38.59
|
336,019
USD
|
|
2015-01-15 |
2015-01-13 |
S
Sale
|
Blumenkranz Mark S.
Non-Executive Director
|
100,000
-13.4%
55.46
5,546,000
USD
|
100,000
-13.4%
|
55.46
|
5,546,000
USD
|
|
2015-01-15 |
2015-01-13 |
S
Sale
|
Wachter Paul
Non-Executive Director
|
14,000
-22.2%
55.46
776,440
USD
|
14,000
-22.2%
|
55.46
|
776,440
USD
|
|
2015-01-15 |
2015-01-13 |
S
Sale
|
Chalberg Thomas W.
Chief Executive Officer
Executive Director
|
85,000
-22.9%
55.46
4,714,100
USD
|
85,000
-22.9%
|
55.46
|
4,714,100
USD
|
|
2015-01-15 |
2015-01-13 |
S
Sale
|
Zygtech, LLC
Major owner
|
100,000
-3.9%
55.46
5,546,000
USD
|
100,000
-3.9%
|
55.46
|
5,546,000
USD
|
|
2015-01-15 |
2015-01-13 |
S
Sale
|
Schwartz Steven Daniel
Non-Executive Director
|
91,000
-16.3%
55.46
5,046,860
USD
|
91,000
-16.3%
|
55.46
|
5,046,860
USD
|
|
2014-08-07 |
2014-08-05 |
B
Purchase
|
Venrock Healthcare Capital Partners II, L.P.
Major owner
|
400,000
+20.4%
17.00
6,800,000
USD
|
400,000
+20.4%
|
17.00
|
6,800,000
USD
|
|
2014-08-07 |
2014-08-05 |
B
Purchase
|
Venrock Associates VI, L.P.
Major owner
|
400,000
+20.4%
17.00
6,800,000
USD
|
400,000
+20.4%
|
17.00
|
6,800,000
USD
|
|
2014-08-05 |
2014-08-05 |
B
Purchase
|
REGENERON PHARMACEUTICALS INC
Major owner
|
588,235
+48.2%
17.00
9,999,995
USD
|
588,235
+48.2%
|
17.00
|
9,999,995
USD
|
|
2014-08-05 |
2014-08-05 |
B
Purchase
|
Flynn James E
Major owner
|
31,650
+5.3%
24.57
777,641
USD
|
31,650
+5.3%
|
24.57
|
777,641
USD
|
|
2014-08-05 |
2014-08-05 |
B
Purchase
|
Flynn James E
Major owner
|
49,981
+9.2%
26.35
1,316,999
USD
|
49,981
+9.2%
|
26.35
|
1,316,999
USD
|
|
2014-08-05 |
2014-08-05 |
B
Purchase
|
Flynn James E
Major owner
|
27,600
+5.3%
26.14
721,464
USD
|
27,600
+5.3%
|
26.14
|
721,464
USD
|
|
2014-08-05 |
2014-08-05 |
B
Purchase
|
Flynn James E
Major owner
|
12,400
+2.5%
27.54
341,496
USD
|
12,400
+2.5%
|
27.54
|
341,496
USD
|
|
2014-08-05 |
2014-08-05 |
B
Purchase
|
Flynn James E
Major owner
|
219,864
+76.9%
26.42
5,808,807
USD
|
219,864
+76.9%
|
26.42
|
5,808,807
USD
|
|
2014-08-05 |
2014-08-05 |
B
Purchase
|
Flynn James E
Major owner
|
18,700
+7.0%
25.79
482,273
USD
|
18,700
+7.0%
|
25.79
|
482,273
USD
|
|
2014-08-05 |
2014-08-05 |
B
Purchase
|
Flynn James E
Major owner
|
9,800
+3.8%
25.52
250,096
USD
|
9,800
+3.8%
|
25.52
|
250,096
USD
|
|
2014-08-05 |
2014-08-05 |
B
Purchase
|
Flynn James E
Major owner
|
201,972
+365.2%
25.41
5,132,109
USD
|
201,972
+365.2%
|
25.41
|
5,132,109
USD
|
|
2014-08-05 |
2014-08-05 |
B
Purchase
|
Flynn James E
Major owner
|
55,300
+inf%
17.00
940,100
USD
|
55,300
+inf%
|
17.00
|
940,100
USD
|
|
2014-08-05 |
2014-08-05 |
B
Purchase
|
Flynn James E
Major owner
|
25,600
+5.3%
24.57
628,992
USD
|
25,600
+5.3%
|
24.57
|
628,992
USD
|
|
2014-08-05 |
2014-08-05 |
B
Purchase
|
Flynn James E
Major owner
|
40,400
+9.2%
26.35
1,064,540
USD
|
40,400
+9.2%
|
26.35
|
1,064,540
USD
|
|
2014-08-05 |
2014-08-05 |
B
Purchase
|
Flynn James E
Major owner
|
22,400
+5.3%
26.14
585,536
USD
|
22,400
+5.3%
|
26.14
|
585,536
USD
|
|
2014-08-05 |
2014-08-05 |
B
Purchase
|
Flynn James E
Major owner
|
10,100
+2.5%
27.54
278,154
USD
|
10,100
+2.5%
|
27.54
|
278,154
USD
|
|
2014-08-05 |
2014-08-05 |
B
Purchase
|
Flynn James E
Major owner
|
177,700
+76.9%
26.42
4,694,834
USD
|
177,700
+76.9%
|
26.42
|
4,694,834
USD
|
|
2014-08-05 |
2014-08-05 |
B
Purchase
|
Flynn James E
Major owner
|
15,100
+7.0%
25.79
389,429
USD
|
15,100
+7.0%
|
25.79
|
389,429
USD
|
|
2014-08-05 |
2014-08-05 |
B
Purchase
|
Flynn James E
Major owner
|
7,900
+3.8%
25.52
201,608
USD
|
7,900
+3.8%
|
25.52
|
201,608
USD
|
|
2014-08-05 |
2014-08-05 |
B
Purchase
|
Flynn James E
Major owner
|
163,300
+365.3%
25.41
4,149,453
USD
|
163,300
+365.3%
|
25.41
|
4,149,453
USD
|
|
2014-08-05 |
2014-08-05 |
B
Purchase
|
Flynn James E
Major owner
|
44,700
+inf%
17.00
759,900
USD
|
44,700
+inf%
|
17.00
|
759,900
USD
|
|
2014-08-05 |
2014-08-05 |
B
Purchase
|
Flynn James E
Major owner
|
123,077
+23.2%
17.00
2,092,309
USD
|
123,077
+23.2%
|
17.00
|
2,092,309
USD
|
|
2014-08-05 |
2014-08-05 |
B
Purchase
|
Flynn James E
Major owner
|
34,223
+23.2%
17.00
581,791
USD
|
34,223
+23.2%
|
17.00
|
581,791
USD
|
|
2014-08-05 |
2014-08-05 |
B
Purchase
|
Flynn James E
Major owner
|
42,700
+23.1%
17.00
725,900
USD
|
42,700
+23.1%
|
17.00
|
725,900
USD
|
|